Orexigen Therapeutics to Present at the J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Thursday, January 12th at 9:00 a.m. PST (12:00 p.m. EST). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
Corporate Contacts: Orexigen |
|
Orexigen |
Media |
Jay Hagan |
Denise Powell |
Chief Business Officer |
WCG |
(858) 875-8673 |
510.703.9491 |
SOURCE Orexigen Therapeutics, Inc.
Share this article